Viloxazine
Brand names: Qelbree · Active ingredient: Viloxazine Hydrochloride
In short: Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
What is Viloxazine used for?
Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
âš Boxed warning (FDA's strongest warning)
In clinical studies, higher rates of suicidal thoughts and behavior were reported in patients with ADHD treated with Qelbree than in patients treated with placebo.
Closely monitor all Qelbree-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors
.
Viloxazine dosage
Assess heart rate and blood pressure prior to initiating treatment with Qelbree, following increases in dosage, and periodically while on therapy
.
Prior to initiating treatment with Qelbree, screen patients for a personal or family history of suicide, bipolar disorder, and depression
.
Pediatric patients
The recommended starting dosage for pediatric patients 6 to 11 years of age is 100 mg orally once daily. Dosage may be titrated in increments of 100 mg at weekly intervals to the maximum recommended dosage of 400 mg once daily, depending on response and tolerability.
The recommended starting dosage for pediatric patients 12 to 17 years of age is 200 mg orally once daily. After 1 week, dosage may be titrated by an increment of 200 mg to the maximum recommended dosage of 400 mg once daily, depending on response and tolerability.
Adult patients
The recommended starting dosage for adults is 200 mg orally once daily. Dosage may be titrated in increments of 200 mg weekly to the maximum recommended dosage of 600 mg once daily, depending on response and tolerability.
Pharmacological treatment of ADHD may be needed for extended periods. Periodically reevaluate the long-term use of Qelbree and adjust dosage as needed.
Administer Qelbree orally with or without food
. Do not cut, crush, or chew the capsules.
Swallow Qelbree capsules whole, or open the capsule and sprinkle the entire contents over a teaspoonful or tablespoonful of pudding or applesauce. Consume the food mixture in its entirety, without chewing, within 15 minutes for pudding, or within 2 hours for applesauce; do not store for future use.
In patients with severe renal impairment (eGFR < 30 mL/min/1.73m
2), the recommended starting dosage is 100 mg once daily. Dosage may be titrated in weekly increments of 50 to 100 mg once daily, to a maximum recommended dosage of 200 mg once daily.
No dosage adjustment is recommended in patients with mild to moderate (eGFR of 30 to 89 mL/min/1.73m
2) renal impairment
.
How to take Viloxazine — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Suicidal Thoughts and Behaviors
Advise patients and caregivers to monitor for the emergence of suicidal thoughts or behaviors or symptoms that might be precursors to emerging suicidal ideation or behavior, especially early during treatment and when the dosage is adjusted up or down. Instruct patients and caregivers to report such symptoms to the healthcare provider
.
Concomitant Use with Monoamine Oxidase Inhibitors (MAOI)
Caution patients about the concomitant use of Qelbree and monoamine oxidase inhibitors (MAOI), or within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
.
Blood Pressure and Heart Rate Increases
Instruct patients that Qelbree can cause elevations of their blood pressure and pulse rate and they should be monitored for such effects
.
Activation of Mania/Hypomania
Advise patients and their caregivers to look for signs of activation of mania/hypomania
.
Somnolence and Fatigue
Advise patients about the potential for somnolence (including sedation and lethargy) and fatigue. …
Warnings & precautions
Do not take this medicine if: Qelbree is contraindicated in patients:
receiving concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, because of an increased risk of hypertensive crisis
.
receiving concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range
.
Higher rates of suicidal thoughts and behaviors were reported in pediatric and adult patients with ADHD treated with Qelbree than in patients treated with placebo.
Among 1019 pediatric patients exposed to Qelbree 100 mg to 400 mg in short-term trials, a total of nine patients (0.9%) reported suicidal ideation (N=6), behavior (N=1) or both (N=2). Eight patients reported suicidal ideation or behavior on the Columbia Suicide Severity Rating Scale (C-SSRS), a validated scale that assesses suicide risk. An additional patient treated with Qelbree reported suicidal behavior during the clinical trials, but did not report it on the C-SSRS. Among 463 patients treated with placebo in these studies, two patients (0.4%) reported suicidal ideation on the C-SSRS. No patients treated with placebo reported suicidal behavior. No completed suicides occurred in these trials.
Among 189 adults treated with Qelbree, a total of three patients (1.6%) reported suicidal ideation on the C-SSRS, versus 0 of 183 adults treated with placebo. No adults treated with either Qelbree or placebo reported suicidal behavior on the C-SSRS in the study. No attempted or completed suicides occurred in the trial.
Patients treated with Qelbree had higher rates of insomnia and irritability
. …
Viloxazine side effects
The following serious adverse reactions are described in other sections of the labeling:
Suicidal Thoughts and Behaviors
Blood Pressure and Heart Rate Increases
Activation of Mania or Hypomania
Somnolence and Fatigue
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of Qelbree has been evaluated in 1118 pediatric patients (6 to 17 years of age) with ADHD exposed to one or more doses in short-term (6 to 8 week), randomized, double-blind, placebo-controlled trials. A total of 682 pediatric patients 6 to 17 years of age were treated for at least 6 months, and 347 pediatric patients 6 to 17 years of age for at least 12 months with Qelbree.
The safety of Qelbree has been evaluated in 189 adult patients (18 to 60 years of age) with ADHD exposed to one or more doses in a short-term (6 week), randomized, double-blind, placebo-controlled trial. A total of 277 adult patients with ADHD have been exposed to one or more doses of Qelbree. Eighty-four adult patients were treated for at least 6 months, and 22 adult patients for at least 12 months. …
Drug interactions
Monoamine Oxidase Inhibitors (MAOI)
Clinical Impact | Concomitant use of Qelbree with an MAOI may lead to a potentially life-threatening hypertensive crisis.
Intervention | Concomitant use of Qelbree with an MAOI or within 2 weeks after discontinuing an MAOI is contraindicated
.
Sensitive CYP1A2 Substrates or CYP1A2 Substrates with a Narrow Therapeutic Range
Clinical Impact | Viloxazine is a strong CYP1A2 inhibitor. Concomitant use of viloxazine significantly increases the total exposure, but not peak exposure, of sensitive CYP1A2 substrates
, which may increase the risk of adverse reactions associated with these CYP1A2 substrates.
Intervention | Coadministration with Qelbree is contraindicated
.
Moderate Sensitive CYP1A2 Substrate
Clinical Impact | Viloxazine is a strong CYP1A2 inhibitor. Concomitant use of viloxazine significantly increases the total, but not peak, exposure of sensitive CYP1A2 substrates
, which may increase the risk of adverse reactions associated with these CYP1A2 substrates.
Intervention | Not recommended for coadministration with Qelbree. Dose reduction may be warranted if coadministered.
CYP2D6 Substrates
Clinical Impact | Viloxazine is a weak inhibitor of CYP2D6, and increases the exposure of CYP2D6 substrates when coadministered
. …
About this medicine
Qelbree contains viloxazine, a selective norepinephrine reuptake inhibitor, in the form of viloxazine hydrochloride which is (±)-2-[(2-ethoxyphenoxy)methyl]morpholine hydrochloride. The molecular formula is C
13H
20NO
3Cl and its molecular weight is 273.8 (HCl salt) with the following structural formula:
Viloxazine hydrochloride is a white to off-white powder. Viloxazine hydrochloride is soluble in water, 0.1N HCl and aqueous solutions of pH 9.5 and lower. Viloxazine hydrochloride is sparingly soluble in methanol, very slightly soluble in acetonitrile, acetic acid and isopropyl alcohol, and practically insoluble in ethyl acetate.
Qelbree extended-release capsules are intended for oral administration. Each extended-release capsule contains 100 mg, 150 mg, and 200 mg of viloxazine free base equivalent to 115mg, 173mg, and 231mg, respectively, of viloxazine hydrochloride salt. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID aedf408d-0f84-418d-9416-7c39ddb0d29a. Read the full official label on DailyMed.